卡瑞利珠单抗联合调强适形放疗用于非小细胞肺癌患者的效果

Effects of Camrelizumab combined with intensity modulated conformal radiation therapy in treatment of patients with non-small cell lung cancer

目的:观察卡瑞利珠单抗联合调强适形放疗用于非小细胞肺癌(NSCLC)患者的效果。方法:选取2021年1月至2023年2月该院收治的80例NSCLC患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各40例。对照组采用调强适形放疗,观察组在对照组基础上联合卡瑞利珠单抗治疗。比较两组临床疗效,治疗前后肿瘤标志物[糖类抗原125(CA125)、蛋白激酶B(PKB)、脂肪酸合成酶(FAS)]水平、血清学指标[肿瘤特异性生长因子(TSGF)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(b-FGF)]水平,以及不良反应发生率。结果:观察组客观缓解率(ORR)为72.50%(29/40),高于对照组的50.00%(20/40),差异有统计学意义(P<0.05);治疗后,观察组CA125、PKB、FAS水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组TSGF、VEGF、b-FGF水平均低于对照组,差异有统计学意义(P<0.05);两组白细胞减少、贫血、血小板减少、放射性肺炎、恶心呕吐等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合调强适形放疗用于NSCLC患者可提高ORR,降低肿瘤标志物、血清学指标水平,效果优于单纯调强适形放疗。

Objective:To observe effects of Camrelizumab combined with intensity modulated conformal radiation therapy in treatment of patients with non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 80 patients with NSCLC admitted to the hospital from January 2021 to February 2023.According to the random number table method,they were divided into control group and observation group,40 cases in each group.The control group was treated with intensity modulated conformal radiation therapy,while the observation group was treated with Camrelizumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[carbohydrate antigen 125(CA125),protein kinase B(PKB),fatty acid synthase(FAS)],the serological indexes[tumor specific growth factor(TSGF),vascular endothelial growth factor(VEGF),basic fibroblast growth factor(b-FGF)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate(ORR)of the observation group was 72.50%(29/40),which was higher than 50.00%(20/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CA125,PKB and FAS in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TSGF,VEGF and b-FGF in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as leukopenia,anemia,thrombocytopenia,radiation pneumonia,nausea and vomiting between the two groups(P>0.05).Conclusions:Camrelizumab combined with intensity modulated conformal radiation therapy in the treatment of the NSCLC patients can improve ORR,reduce the levels of tumor markers and serological indexes.Moreover,it is superior to single intensity modulated conformal radiation therapy.